A Phase 4 interventional study of Itraconazole in Pulmonary Fungal Infection, sponsored by Xian-Janssen Pharmaceutical Ltd.. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-05-31.
Sponsored by Xian-Janssen Pharmaceutical Ltd. (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the efficacy and safety of itraconazole sequential therapy (intravenous injection/oral solution) in participants with invasive pulmonary fungal infections ([IPFI]; lung diseases caused by fungal infection).
This is an open-label (all people know the identity of the intervention), single arm, multicenter (when more than one hospital or medical school team work on a medical research study) study to evaluate the efficacy and safety of itraconazole sequential therapy in participants with IPFI. The study duration will be 4 to 6 weeks. The treatment will be divided into the intravenous (into a vein) injection period and the oral solution administration (giving) period. During the intravenous injection period 200 milligram (mg) twice daily loading dose (large initial dose) will be given for first 2 days, 200 mg once daily for the subsequent 12 days. Then sequential itraconazole oral solution 200 mg twice daily will be given as maintenance therapy (treatment designed to help the original primary treatment to succeed) for 2-4 weeks. Participant's clinical, mycological and comprehensive efficacy will be assessed at Week 6. Participants' safety will be monitored throughout the study.
Xian-Janssen Pharmaceutical Ltd. is the lead sponsor of 36 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Itraconazole
Itraconazole 200 milligram (mg) intravenous injection will be given twice daily for first 2 days, 200 mg once daily for the subsequent 12 days, then sequential itraconazole oral solution 200 mg twice daily will be given for 2 to 4 weeks.
Number of Participants With Clinical Efficacy
Clinical efficacy was assessed as cured: the signs and symptoms of invasive fungal infections (IFI) completely disappeared or full or nearby resolution of radiographic manifestations; markedly improved: the signs and symptoms of IFI were improved or disappeared and at least 50 percent improvement of radiographic findings; improved: the signs and symptoms of IFI were moderately improved and less than 50 percent improvement of radiographic findings; failed: the clinical symptoms and signs of IFI were not changed or worsened.
Time frame: Week 6
Number of Participants With Mycological Efficacy
Mycological efficacy was assessed as fungi cleared: negative for fungal microscopic examination and culture (test for infection or organisms that could cause infection); fungi not cleared: positive for fungal microscopic examinations and/or culture.
Time frame: Week 6
Number of Participants With Comprehensive Efficacy
Comprehensive efficacy was assessed as cured: the symptoms, signs, laboratory examination and pathogenic examination were return to normal; markedly improved: the disease condition was markedly improved but symptoms, signs, laboratory examination and pathogenic examination were not return to normal; improved: the disease condition was improved to some extent after drug administration, but the improvement was not significant enough; failed: the disease condition was not improved significantly or worsened after drug administration.
Time frame: Week 6
| Milestone | Itraconazole Sequential Therapy |
|---|---|
| Started | 71 |
| Completed | 47 |
| Not completed | 24 |
| Withdrew: Lost to follow-up | 5 |
| Withdrew: Adverse event | 5 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Physician decision | 9 |
| Withdrew: Administered contraindicated medicine | 1 |
| Withdrew: Transaminase increased more than 3 times | 1 |
| Withdrew: Drug affected efficacy and safety | 1 |
| Withdrew: Creatinine clearance<30milliliter/minute | 1 |
Clinical efficacy was assessed as cured: the signs and symptoms of invasive fungal infections (IFI) completely disappeared or full or nearby resolution of radiographic manifestations; markedly improved: the signs and symptoms of IFI were improved or disappeared and at least 50 percent improvement of radiographic findings; improved: the signs and symptoms of IFI were moderately improved and less than 50 percent improvement of radiographic findings; failed: the clinical symptoms and signs of IFI were not changed or worsened.
| participants | Itraconazole Sequential Therapy |
|---|---|
| Cured | 8 |
| Markedly Improved | 29 |
| Improved | 18 |
| Failed | 5 |
Mycological efficacy was assessed as fungi cleared: negative for fungal microscopic examination and culture (test for infection or organisms that could cause infection); fungi not cleared: positive for fungal microscopic examinations and/or culture.
| participants | Itraconazole Sequential Therapy |
|---|---|
| Fungi cleared | 20 |
| Fungi not cleared | 10 |
Comprehensive efficacy was assessed as cured: the symptoms, signs, laboratory examination and pathogenic examination were return to normal; markedly improved: the disease condition was markedly improved but symptoms, signs, laboratory examination and pathogenic examination were not return to normal; improved: the disease condition was improved to some extent after drug administration, but the improvement was not significant enough; failed: the disease condition was not improved significantly or worsened after drug administration.
| participants | Itraconazole Sequential Therapy |
|---|---|
| Cured | 8 |
| Markedly Improved | 32 |
| Improved | 16 |
| Failed | 4 |
Collected over From the signing of informed consent until end of the study (week 6).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Itraconazole Sequential Therapy | — | 4/61 (6.6%) | 13/61 (21.3%) |
| Event | Itraconazole Sequential Therapy |
|---|---|
| DeathGeneral disorders | 2/61 |
| EdemaGeneral disorders | 1/61 |
| Fungal infectionImmune system disorders | 1/61 |
| HemoptysisRespiratory, thoracic and mediastinal disorders | 1/61 |
| Event | Itraconazole Sequential Therapy |
|---|---|
| HypokalaemiaMetabolism and nutrition disorders | 3/61 |
| Hepatic function abnormalHepatobiliary disorders | 3/61 |
| NauseaGastrointestinal disorders | 2/61 |
| DiarrheaGastrointestinal disorders | 2/61 |
| GranulocytopeniaBlood and lymphatic system disorders | 1/61 |
| HyperbilirubinemiaHepatobiliary disorders | 1/61 |
| GPT increasedHepatobiliary disorders | 1/61 |
| Urinary tract infectionRenal and urinary disorders | 1/61 |
| Renal function abnormalRenal and urinary disorders | 1/61 |
| DermatosesSkin and subcutaneous tissue disorders | 1/61 |
| Age Continuous(years) | Itraconazole Sequential Therapy |
|---|---|
| Median | 55.5 (33.34 to 79.45) |
| Sex: Female, Male(Participants) | Itraconazole Sequential Therapy |
|---|---|
| Female | 23 |
| Male | 37 |
No study locations are listed for this record.
The record gives a start of Jun 2007, a primary completion of Dec 2008 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.
Results were first posted in May 2013, 4 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Itraconazole
Lung Diseases, Fungal
Xian-Janssen Pharmaceutical Ltd. →